BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast
Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the third quarter 2017 on Friday, 17 November 2017.A presentation by BerGenBio’s senior management team will take place at 9.00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be